Feasibility of Tablet-Based Patient-Reported Symptom Data Collection Among Hemodialysis Patients
© 2020 International Society of Nephrology. Published by Elsevier Inc..
INTRODUCTION: Individuals receiving in-center hemodialysis have high symptom burdens but often do not report their symptoms to care teams. Evidence from other diseases suggest that use of symptom electronic patient-reported outcome measures (ePROMs) may improve outcomes. We assessed the usability of a symptom ePROM system and then implemented a quality improvement (QI) project with the objective of improving symptom communication at a US hemodialysis clinic. During the project, we assessed the feasibility of ePROM implementation and conducted a substudy exploring the effect of ePROM use on patient-centered care.
METHODS: After conducting usability testing, we used mixed methods, guided by the Quality Implementation Framework, to implement a 16-week symptom ePROM QI project. We performed pre-, intra-, and postproject stakeholder interviews to identify implementation barriers and facilitators. We collected ePROM system-generated data on symptoms, e-mail alerts, and response rates, among other factors, to inform our feasibility assessment. We compared pre- and postproject outcomes.
RESULTS: There were 62 patient participants (34% black, 16% Spanish-speaking) and 19 care team participants (4 physicians, 15 clinic personnel) at QI project start, and 32 research participants. In total, the symptom ePROM was administered 496 times (completion rate = 84%). The implementation approach and ePROM system were modified to address stakeholder-identified concerns throughout. ePROM implementation was feasible as demonstrated by the program's acceptability, demand, implementation success, practicality, integration in care, and observed trend toward improved outcomes.
CONCLUSIONS: Symptom ePROM administration during hemodialysis is feasible. Trials investigating the effectiveness of symptom ePROMs and optimal administration strategies are needed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Kidney international reports - 5(2020), 7 vom: 18. Juli, Seite 1026-1039 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Flythe, Jennifer E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hemodialysis |
|---|
| Anmerkungen: |
Date Revised 15.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ekir.2020.04.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312245599 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312245599 | ||
| 003 | DE-627 | ||
| 005 | 20231225144010.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ekir.2020.04.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1040.xml |
| 035 | |a (DE-627)NLM312245599 | ||
| 035 | |a (NLM)32647760 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Flythe, Jennifer E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Feasibility of Tablet-Based Patient-Reported Symptom Data Collection Among Hemodialysis Patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 International Society of Nephrology. Published by Elsevier Inc. | ||
| 520 | |a INTRODUCTION: Individuals receiving in-center hemodialysis have high symptom burdens but often do not report their symptoms to care teams. Evidence from other diseases suggest that use of symptom electronic patient-reported outcome measures (ePROMs) may improve outcomes. We assessed the usability of a symptom ePROM system and then implemented a quality improvement (QI) project with the objective of improving symptom communication at a US hemodialysis clinic. During the project, we assessed the feasibility of ePROM implementation and conducted a substudy exploring the effect of ePROM use on patient-centered care | ||
| 520 | |a METHODS: After conducting usability testing, we used mixed methods, guided by the Quality Implementation Framework, to implement a 16-week symptom ePROM QI project. We performed pre-, intra-, and postproject stakeholder interviews to identify implementation barriers and facilitators. We collected ePROM system-generated data on symptoms, e-mail alerts, and response rates, among other factors, to inform our feasibility assessment. We compared pre- and postproject outcomes | ||
| 520 | |a RESULTS: There were 62 patient participants (34% black, 16% Spanish-speaking) and 19 care team participants (4 physicians, 15 clinic personnel) at QI project start, and 32 research participants. In total, the symptom ePROM was administered 496 times (completion rate = 84%). The implementation approach and ePROM system were modified to address stakeholder-identified concerns throughout. ePROM implementation was feasible as demonstrated by the program's acceptability, demand, implementation success, practicality, integration in care, and observed trend toward improved outcomes | ||
| 520 | |a CONCLUSIONS: Symptom ePROM administration during hemodialysis is feasible. Trials investigating the effectiveness of symptom ePROMs and optimal administration strategies are needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a hemodialysis | |
| 650 | 4 | |a implementation | |
| 650 | 4 | |a improvement | |
| 650 | 4 | |a mixed methods | |
| 650 | 4 | |a patient-reported outcomes | |
| 650 | 4 | |a quality | |
| 650 | 4 | |a symptoms | |
| 700 | 1 | |a Tugman, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Narendra, Julia H |e verfasserin |4 aut | |
| 700 | 1 | |a Dorough, Adeline |e verfasserin |4 aut | |
| 700 | 1 | |a Hilbert, Johnathan |e verfasserin |4 aut | |
| 700 | 1 | |a Assimon, Magdalene M |e verfasserin |4 aut | |
| 700 | 1 | |a DeWalt, Darren A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international reports |d 2016 |g 5(2020), 7 vom: 18. Juli, Seite 1026-1039 |w (DE-627)NLM264185072 |x 2468-0249 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2020 |g number:7 |g day:18 |g month:07 |g pages:1026-1039 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ekir.2020.04.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2020 |e 7 |b 18 |c 07 |h 1026-1039 | ||